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RNA interference (RNAi) is a phenomenon in which double-
stranded RNA (dsRNA) silences endogenous gene expression. By
injecting pools of dsRNAs into Caenorhabditis elegans, we identi-
fied a dsRNA that acts as a potent suppressor of the RNAi mech-
anism. We have used coinjection of dsRNAs to identify four
additional candidates for genes involved in the RNAi mechanism in
C. elegans. Three of the genes are C. elegans mes genes, some of
which encode homologs of the Drosophila chromatin-binding
Polycomb-group proteins. We have used loss-of-function mutants
to confirm a role for mes-3, -4, and -6 in RNAi. Interestingly,
introducing very low levels of dsRNA can bypass a requirement for
these genes in RNAi. The finding that genes predicted to encode
proteins that associate with chromatin are involved in RNAi in C.
elegans raises the possibility that chromatin may play a role in RNAi
in animals, as it does in plants.
RNA interference (RNAi) works in a remarkable variety oforganisms, including animals, plants, fungi, and protists
(1–4). RNAi can be used as a tool to phenocopy the loss of
function of one specific gene at a time (5), and it has been
exploited in screens designed to identify developmental genes, by
injecting pools of multiple double-stranded RNAs (dsRNAs)
into animals and examining phenotypes in their progeny (6–10).
The process by which dsRNA silences gene activity is not
completely understood, although the mechanism is known to
involve cleavage of both the dsRNA and the corresponding
endogenous mRNA into 21–25 nucleotide fragments (11–14).
Cleavage of the dsRNA in animal cells requires Dicer, a member
of the RNase III family of nucleases (15–17). To date, only a
handful of other proteins have been implicated in RNAi in
animal cells, and all of these are predicted to interact with
RNA—an RNaseD-like protein, an RNA-dependent RNA poly-
merase-like protein, and an eIF2C-like protein (18–20). Some of
the Caenorhabditis elegans smg genes, which participate in non-
sense-mediated mRNA decay, are required for the RNAi effect
to persist (21). In plants and fungi, RNAi has been proposed to
additionally involve chromatin, because RNAi-like phenomena
require proteins predicted to interact with chromatin—a SWI2
SNF2 component, a DNA methyltransferase, and a DNA heli-
case-like protein (22–25)—as well as proteins predicted to
interact with RNA (22, 26). No such role for chromatin has yet
been implicated in animal cells.
We have fortuitously identified a dsRNA that acts as a potent
suppressor of the RNAi mechanism. Here, we describe the
method we used and additional genes with potential roles in
RNAi that we have identified by using this approach.
Materials and Methods
Strains. C. elegans was maintained as in ref. 27. Strains and alleles
used were Bristol Strain N2 (wild type), SS186: mes-2(bn11)
unc-4(e120)mnC1 dpy-10(e128) unc-52(e444)II, SS262: mes-
3(bn35) dpy-5(e61)I; sDp2(I;f), SS268: dpy-11(e224) mes-4(bn23)
unc-76(e911)VnT1(IV;V), JK2663: dpy-11(e224) mes-4(bn67)
VnT1(IV;V), SS222: mes-3(bn21)I, SS282: mes-6(bn64); dpy-
11(e224)nT1(IV;V), SS360: mes-6(bn66) dpy-20(e1282)IV
nT1(IV;V).
dsRNA Preparation and Injection. Templates for in vitro transcrip-
tion were generated by a two-step PCR from wild-type genomic
DNA. Primers for the first step included 20 bases specific to the
target sequence and 15 bases of the T7 promoter sequence. The
resulting PCR product was purified by using a Qiagen (Chats-
worth, CA) PCR purification kit according to the manufacturer’s
recommendations. This product was used as a template for a
second PCR using oligonucleotides containing the full-length T7
promoter sequence. One to two micrograms of the product were
then gel-purified and used as a template in an in vitro transcrip-
tion reaction by using Ambion’s (Austin, TX) T7 Megascript Kit
according to the manufacturer’s recommendations. The integ-
rity of the dsRNA was assessed by gel electrophoresis, and the
concentration was determined by spectrophotometry. For stor-
age of dsRNAs, the resulting solution was mixed with 2 volumes
of 100% ethanol and kept at 80°C. RNAi-to-RNAi assays were
performed by coinjecting 30 ngl of target dsRNA (for exam-
ple, mom-2) with 100 ngl of test dsRNA (for example, mut-7)
into either the gut or gonad of adult wild-type hermaphrodites.
For each experiment in Fig. 3C, 500 ngl of dsRNA was
injected.
Soaking. Soaking experiments were performed by the method of
Maeda et al. (10) with the following alterations: both wild-type
and mutant worms were incubated together in 8 l of soaking
buffer with either 100 or 800 ngl of dsRNA for 24 h, and
transfers to freshly seeded NGM plates were carried out daily.
Results and Discussion
During a pilot screen aimed at identifying genes with essential
roles in embryogenesis, we found that one pool of eight dsRNAs
that was expected to produce embryonic lethality did not (Fig.
1A): injecting C. elegans adult hermaphrodites with a pool
containing dsRNA corresponding to the essential gene glp-1 (28,
29) and seven other dsRNAs resulted only in viable embryos. In
contrast, injecting the glp-1 dsRNA alone resulted in a high
degree of embryonic lethality (Fig. 1B). To determine whether
the lethality produced by glp-1(RNAi) was being suppressed by
a specific dsRNA in the pool, we coinjected glp-1 dsRNA with
each other dsRNA from the pool. We found that only injection
of a dsRNA corresponding to the M04B2.3 gene could suppress
glp-1 dsRNA-mediated lethality (Fig. 1C). Additionally, remov-
ing the M04B2.3 dsRNA from the pool was sufficient to restore
embryonic lethality on injection (Fig. 1D), indicating that the
glp-1(RNAi) phenotype is not suppressed nonspecifically by
coinjection of multiple other dsRNAs.
M04B2.3 dsRNA might suppress glp-1(RNAi) by suppressing
glp-1 loss of function. Alternatively, it might suppress glp-
1(RNAi) by suppressing the RNAi mechanism. To distinguish
between these possibilities, we first tested whether M04B2.3
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Fig. 1. Using pools of dsRNAs to identify genes that may be required for RNAi. (A) Ten pools injected in the pilot screen and the embryonic lethality that resulted
from each injection. A pyramid of bars under each of the 10 pool numbers represents the results from injecting a pool of eight dsRNAs (top row), two groups
of four dsRNAs (second row), and then single dsRNAs (third row) into hermaphrodites. Each bar is filled to a degree representing the percent embryonic lethality
resulting from that injection (i.e., completely filled bars represent 100% embryonic lethality). Lethality was scored in embryos that were laid the day after
injection by at least 10–15 adults that survived injection. dsRNAs were reinjected in subgroups or as single dsRNAs for each pool that included a dsRNA expected
to produce embryonic lethality (black dot) andor was found to result in more than 20% embryonic lethality. All other subgroups or single dsRNAs, which were
not injected, are represented as empty gray bars. As can be seen, 10 dsRNAs expected to produce embryonic lethality based on their published mutant andor
RNAi phenotypes were present in seven of the 10 pools. Of these seven pools, only pool 2 failed to produce embryonic lethality. An asterisk marks the M04B2.3
dsRNA, in pool 2. The black bar next to M04B2.3 represents the glp-1 dsRNA. dsRNAs injected were the following, (Left to Right): pool 1 (C03C10.3, C25A1.8,
EEED8.3, F56G4.3, F31F6.3, T05F1.2, C04F12.9, F33G12.4), pool 2 (F14B6.3, F40G12.11, Y11D7A.13, C50E3.13, C17E7.4, F02A9.6, M04B2.3, C16C8.16), pool 3
(C49F5.6, C38D9.2, D1009.2, C27C12.1, T22A3.7, B0416.4, F54D10.7, C01F6.4), pool 4 (C52D10.7, K07A1.2, F22B3.4, K04C1.5, F54D10.5, F45C12.7, T06E6.2,
T11F8.3), pool 5 (ZK484.3, C27D9.1, C14B1.9, F52B5.2, F56G4.2, H02I12.1, F35C8.7, F19H6.4), pool 6 (F10G2.2, C25D7.6, K08E4.2, F40F8.9, T02C12.3, C32E8.8,
C17E7.9, ZK632.1), pool 7 (F38E1.7, D2024.5, F20B6.7, R04D3.3, C29A12.3, ZK863.4, K05C4.6, C52D10.8), pool 8 (DY3.7, F17C11.10, F28D1.2, K08A8.1, C50B6.3,
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dsRNA could suppress glp-1 loss-of-function mutations. Injec-
tion of M04B2.3 dsRNA failed to suppress the lethality produced
by two glp-1 alleles, q231, and q224 (28) (data not shown). Next,
we determined whether M04B2.3 dsRNA suppresses the RNAi
mechanism by testing whether it could suppress the lethality
produced by other dsRNAs. We found that M04B2.3 dsRNA was
able to suppress the lethality produced by RNAi of several
structurally unrelated, essential genes (Fig. 1E), suggesting that
M04B2.3 dsRNA is a potent suppressor of the RNAi mechanism.
M04B2.3 appears to be relatively unique in its ability to
suppress the phenotypes of coinjected dsRNAs, because none of
the other genes tested in the pilot screen produced a similar
effect. The pilot screen comprised 10 pools of eight dsRNAs, all
of which correspond to transcripts that are enriched in C. elegans
oocytes in comparison to somatic tissues (30). Seven of the 10
pools included dsRNAs corresponding to genes already known
to be essential for embryogenesis, and all of these pools, except
the one that included M04B2.3 and glp-1, resulted in embryonic
lethality (Fig. 1 A). Injections of subsets of dsRNAs from each of
these pools revealed that every dsRNA expected to produce
embryonic lethality did so, with the exception of glp-1 dsRNA.
Because the pools included only one suppressor (M04B2.3) and
38 dsRNAs that neither produced lethality themselves nor
suppressed the phenotypes of coinjected previously known lethal
dsRNAs, we estimate that very few dsRNAs corresponding to
germline-enriched transcripts can suppress RNAi in pools.
Suppression of RNAi by M04B2.3 dsRNA might be caused by
loss of M04B2.3 mRNA. Alternatively, the M04B2.3 dsRNA
might suppress RNAi, because it contains a specific dsRNA
sequence that is a potent competitor for the RNAi machinery;
to test this, we generated dsRNAs corresponding to the 5 and
3 halves of the M04B2.3 gene and coinjected either half with
mom-2 or glp-1 dsRNAs. If a specific sequence in the M04B2.3
dsRNA is a strong competitor for the RNAi machinery, we
would expect only the half that contained this sequence to
suppress RNAi, whereas if M04B2.3 is required for RNAi, we
would expect both halves to suppress RNAi. We found that both
of these dsRNAs suppressed the lethality produced by mom-2
and glp-1 dsRNAs (data not shown); this and further results
below suggest that suppression is produced by loss of M04B2.3
mRNA.
These results suggest that injecting multiple dsRNAs can be
used as an efficient method to identify genes required for RNAi.
Others have found recently that RNAi of C. elegans and fly
versions of Dicer and fly Argonaute2 can reduce the effectiveness
of RNAi of particular genes (15, 16, 31). We asked whether
RNAi of additional known components of the RNAi machinery
could also suppress phenotypes associated with these dsRNAs.
dsRNAs corresponding to two genes required for RNAi, mut-7
and rde-1 (18, 20), were each coinjected with either mom-2 or
hmp-2 dsRNA. Like M04B2.3, both rde-1 and mut-7 were able to
suppress the embryonic lethality produced by RNAi of mom-2
or hmp-2, whereas control dsRNAs could not (Fig. 1F). On the
basis of these results and of our results from the pool from which
M04B2.3 was identified, we conclude that injecting as many as
eight dsRNAs at a time can be used as an efficient method to
identify candidates for genes involved in the RNAi mechanism
in C. elegans. For convenience, we refer to the injection of
multiple dsRNAs for this purpose as an RNAi-to-RNAi assay.
A BLAST search revealed that the M04B2.3 gene (Fig. 2A) has
strong similarity to a human gene, GAS41, which was found as
an amplified gene in glioblastomas (32, 33). We therefore refer
to the M04B2.3 gene as gfl-1, for GAS41-like. Both the human
GAS41 and C. elegans GFL-1 proteins are predicted to associate
with DNA, based on the presence of an acidic domain and on
sequence similarity to a conserved domain of the predicted
chromatin-modifying protein TFIIF. GAS41 has been found to
bind another human protein, the leukemia translocation protein
AF10, by yeast two-hybrid, GST pulldown, and coimmunopre-
cipitation assays (34). Because the human AF10 gene has strong
similarity to a C. elegans gene, zfp-1 (both share predicted
LAPPHD finger, zinc finger, and leucine-rich domains; Fig.
2B), we tested whether RNAi of zfp-1 also suppresses RNAi. We
found that injection of zfp-1 dsRNA suppressed the lethality
produced by mom-2 and hmp-2 dsRNAs (Fig. 3A), suggesting
that like gfl-1, the zfp-1 gene may also be required for RNAi.
Two other human genes with sequence similarity to GAS41,
AF-9 and ENL, encode proteins that can bind human Polycomb
3 (35). We therefore tested whether C. elegans polycomb-group
genes are required for RNAi. Only two Drosophila polycomb-
group genes, Enhancer of zeste and extra sex combs, have
recognizable C. elegans homologs, named mes-2 and -6, respec-
tively, for their maternal effect sterile loss-of-function pheno-
types (36, 37). MES-2 and -6 proteins exist in a complex with a
novel protein, MES-3 (38). mes-2, -3, -6, and a gene with some
similarity to mes-2, called mes-4, are each required maternally for
Fig. 2. (A) Diagram of C. elegans GFL-1 (M04B2.3), which has a predicted
length of 211 aa, and Human GAS41 (32, 33), which has a predicted length of
227 aa. The two proteins share 50% amino acid identity over 200 aa. The acidic
domain comprises 27% acidic residues over 60 aa for GAS41 and 25% acidic
residues over 61 aa for GFL-1. (B) Diagram of C. elegans ZFP-1, which has a
predicted length of 867 aa, and Human AF10, which has a predicted length of
1,027 aa. Percents amino acid identity in two regions are shown. PHDLAP
refers to plant homeodomainleukemia-associated protein finger (50, 51).
T01G9.5, B0393.3, T20B12.8), pool 9 (F26G1.1, B0393.2, ZK154.5, F31E8.4, F21G4.2, ZC53.7, T04A8.7, C36B1.12), and pool 10 (W06E11.1, C27A2.6, K01G5.4,
T04A8.8, F11C1.2, R10E4.4, T23B12.6, ZK154.7). DY3.7 does not have a black dot despite being an essential gene (48), because others have shown that RNAi of
DY3.7 does not produce a phenotype (49). (B–F) Each graph represents the results from an experiment in which gravid adult hermaphrodites were injected, and
a minimum of 10–15 surviving adults were transferred to new plates periodically over the next 1–3 days, leaving the embryos laid between transfers on plates.
Embryonic lethality was scored at least 24 h after the adults were removed from each plate. Each dark gray box shows the percent of embryos that failed to hatch
(y axis) during a particular time window (x axis). Because each experiment includes an embryonic lethal dsRNA, low percent lethality reveals that a suppressor
was coinjected. All unlabeled axes are as in B; vertical ticks mark lethality in 25% intervals and horizontal ticks mark time at 12 h intervals. (B) Lethality produced
by a pool of eight dsRNAs that included glp-1 dsRNA and by glp-1 dsRNA alone. (C) Lethality produced by glp-1 dsRNA coinjected with individual dsRNAs from
the pool. dsRNAs nos. 2, 3, 4, 5, 7, and 8 correspond to C. elegans genes C17E7.4, C16C8.16, F14B6.3, Y11D7A.13, C50E3.13, F40G12.11, respectively, derived from
a collection of genes with germline-enriched transcripts (30). (D) Lethality produced by the pool with and without M04B2.3 dsRNA. (E) Lethality produced by
five embryonic lethal dsRNAs each on their own and coinjected with M04B2.3 dsRNA. (F) Lethality produced by mom-2 dsRNA injected alone or with mut-7, rde-1,
or control (unc-22 or gfp) dsRNAs. (See Fig. 5, which is published as supporting information on the PNAS web site, for complete results with additional replicates
of these experiments.)








survival of larval germ cells (39, 40). Loss of function of any of
these four mes genes causes a defect in transgene silencing, a
phenotype that has also been seen in mutants deficient in RNAi
(20, 41). We tested each of these four mes genes by the
RNAi-to-RNAi assay, and found that the lethality produced by
mom-2 or pos-1 dsRNA was indeed suppressed by coinjection of
mes-3, -4, or -6 dsRNA, but not by coinjection of mes-2 dsRNA
(Fig. 3B), suggesting that mes-3, -4, and -6 may be required for
RNAi, and that mes-2 is not.
As an important test of our proposal that certain of the mes
genes play roles in RNAi, we determined whether worms bearing
loss-of-function mutations in each of these genes are also
RNAi-deficient. We injected mom-2, hmp-2, or par-2 dsRNAs
into homozygous mes mutant hermaphrodites at a dsRNA
concentration typical for C. elegans RNAi experiments (6, 19)
(see Materials and Methods). Consistent with our RNAi-to-
RNAi results, the lethality produced by each dsRNA was
suppressed in mes-3, -4, and -6 null mutants, and it was not
suppressed in mes-2 null mutants (Fig. 3C).
Our results appear to contradict some of the results of
Tabara et al. (20), who reported that injecting pos-1 dsRNA,
at a concentration just sufficient to produce a high degree of
lethality in wild-type worms, produced high degrees of lethal-
ity in mes-2, -3, -4, and -6 loss-of-function backgrounds. Others
have found previously that C. elegans dcr-1 is required for
RNAi under some but not all conditions (17). We wished to
determine whether this is also true for mes-3, -4, and -6, and
if so, under what conditions these genes are required for RNAi.
We tested whether the disparity between our results and
Tabara et al. (20) could be attributed to differences in which
mes alleles were tested, the specific dsRNAs assayed, or the
concentration of dsRNA injected. For mes-6, our results
revealed that a null allele (see Fig. 3 legend) was RNAi-
deficient, but the weaker allele (37) that had been tested
previously by Tabara et al. (20) was not (Figs. 3C and 4A). For
mes-3 and -4, interestingly, an effect was found to depend on
the concentration of dsRNA injected. Null alleles of mes-3 and
-4 suppressed the effects of injecting typically used (6, 19)
concentrations of dsRNA but, surprisingly, not the effects of
injecting much lower concentrations of dsRNA (Fig. 4B). A
similar, but weaker, concentration dependence was found in
the null mes-6 allele as well (Fig. 4C). We note that this result
is not consistent with, and in fact is the inverse of, what one
might expect from a hypomorphic allele of a gene required for
RNAi. This peculiar effect is also not specific to one mode of
delivery of dsRNA, because introducing dsRNA by soaking
worms in dsRNA, instead of injecting the dsRNA, produced
similar results (Fig. 4C). These results suggest that low con-
Fig. 3. Testing candidate genes for roles in RNAi. All axes are as in Fig. 1B; vertical ticks mark lethality in 25% intervals and horizontal ticks mark time at 12 h
intervals. (A) Lethality produced by mom-2 dsRNA or hmp-2 dsRNA injected with or without zfp-1 dsRNA. (B) Lethality produced by mom-2 alone (top row) or
coinjected with dsRNAs corresponding to mes-2, -3, -4, and -6, or a control (unc-54) dsRNA. (C) Lethality produced by injecting dsRNAs (mom-2, hmp-2, or par-2)
in wild-type N2 worms or mes mutants (labeled along left side), Asterisk indicates that for par-2, bn21ts was tested at 25°C in place of bn35. ND, not determined.
mes-2(bn11), mes-3(bn35), mes-4(bn23), and mes-6(bn64) (an allele with an early stop codon) each appear to be null alleles by immunostaining (refs. 36, 37, 52;
Y. Fong and S. Strome, personal communication), and mes-6(bn66) (a missense allele) was found to produce small amounts of MES-6 protein by immunostaining
(37). RNAi-deficient phenotypes in mes-3, -4, and -6 mutants are unlikely to be caused by genetic background, because these strains were outcrossed multiple
times during construction (39), and because our results with mutants are consistent with our RNAi-to-RNAi results above. (See Fig. 5, which is published as
supporting information, for complete results with additional replicates of these experiments.)
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centrations of dsRNA elicit a response that is uniquely able to
bypass a requirement for mes-3, -4 and, to a lesser degree,
mes-6, in RNAi. MES-2, -3, and -6 are associated in a complex
in C. elegans embryos (38); our results indicate that not all
members of this complex are involved in RNAi. Our results
also suggest that a very low level of mes-6 activity may be
sufficient to function in RNAi, because only a null allele of
mes-6 was RNAi-deficient, and because loss of mes-2 function
does not block RNAi (Figs. 3 B and C and 4C); loss of mes-2
function has been found previously to result in lower levels of
MES-6 protein, levels similar to the weaker of the two mes-6
alleles we tested (37). We conclude from our results that mes-3,
-4, and -6 are required for RNAi under some but not all
conditions.
Our results have identified a total of five candidates for genes
involved in the RNAi mechanism in C. elegans–gfl-1, zfp-1, mes-3,
-4, and -6. For three of these (mes-3, -4, and -6), null mutants
were also RNAi-deficient. Given the complete congruence of
our RNAi-to-RNAi results with our results using mutants, we
would predict that null mutants of the other two genes would also
be RNAi-deficient; however, this remains to be determined. We
have not found any phenotypes other than RNAi deficiency after
RNAi of gfl-1 or zfp-1. Because the RNAi mechanism is silenced
in these experiments, it is not clear whether a phenotype that
would be seen in a loss-of-function mutant would result from
RNAi of these genes; therefore, whether these genes have
additional functions remains to be seen.
All of the genes we have identified encode proteins that are
predicted to associate with chromatin (refs. 36, 37, and 42; S.
Strome, personal communication). RNAi in animals has been
found to work not at the level of DNA but by degrading mRNA, and
mRNA degradation can occur even in the absence of DNA (13).
How then might chromatin play a role in RNAi? Our results to date
can suggest only speculative models. One possibility is that the role
of chromatin is indirect—that inactivation of genes such as the
polycomb-group genes results in transcriptional misregulation that
may block RNAi by saturating the RNAi mechanism with excess
RNA or by down-regulating genes that encode components of the
RNAi mechanism. We consider this unlikely, because RNAi can in
fact occur in strong mes-3 and -4 mutants when dsRNAs are
introduced at low concentration. An alternative hypothesis that is
consistent with current data is that introducing dsRNA in animal
cells might result in both degrading mRNA and also recruiting a
transcriptional silencing complex to the targeted locus. Such a
mechanism might conceivably be required for a penetrant RNAi
effect, by further reducing a pool of endogenous mRNA through
repressing transcription of specific loci. In plants, introduction of
dsRNA can cause both degradation of endogenous transcripts and
silencing of the relevant locus (43), although silencing of the locus
is thought to occur through DNA methylation (43, 44). If dsRNA
does induce gene silencing in C. elegans, it is unlikely that it occurs
through DNA methylation, because little to no DNA methylation
can be detected in C. elegans (45). On the basis of our results, we
have proposed that low concentrations of dsRNA might elicit a
response that is uniquely able to bypass a requirement for mes-3, -4,
and -6 in RNAi. One mechanism that might be active only in the
presence of low concentrations of dsRNA is amplification; it has
been reported recently that dsRNAs can be amplified by short
interfering RNAs (siRNAs) priming the production of new
dsRNAs (46, 47). It will be of interest to determine whether this
amplification mechanism is active only when low concentrations of
dsRNA are introduced, and if so, whether amplification of dsRNAs
might bypass a requirement for mes-3, -4, and -6 in RNAi. If our
model, that dsRNA in animal cells might recruit a transcriptional
silencing complex to the targeted locus, is correct, one might expect
that amplification of dsRNAs could result in RNAi sufficiently
strong and lasting to bypass a requirement for transcriptional
silencing.
As with a standard genetic screen, an RNAi-based screen
would be expected to have the potential to find both direct and
indirect players in the process being studied. Hence, like other
proteins implicated in RNAi by genetics alone (18–21), how
direct a role chromatin-binding proteins play in RNAi remains
to be determined.
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